Patients newly diagnosed (\>9 months) with mild to moderate ulcerative colitis as per colonic biopsy and clinical disease activity (SCCAI 5-12).
Patients not started on immune-suppressive or anti-inflammatory medications (Mesalamine is allowed).
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test, which must be negative, on Study Day 1, prior to receiving FMT. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT.
Ability to understand and the willingness to sign a written document, including the willingness to accept risk of unrelated donor stool.
Ability of parents or other legal guardian to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool.
Ability to swallow oral medications.
You may not be if
Severe, uncontrolled ulcerative colitis.
At time of enrollment, immune-suppressive or anti-inflammatory medications, except Mesalamine.
Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Delayed gastric emptying syndrome
Known chronic aspiration
Patients with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
Pregnant and breast-feeding women
Participants who are unable to swallow pills.
Clareo Health | Capsulized Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis Patients
